Basic Information
| LncRNA/CircRNA Name | HULC |
| Synonyms | HULC, HCCAT1, LINC00078, NCRNA00078 |
| Region | GRCh38_6:8435568-9294133 |
| Ensemble | ENSG00000251164 |
| Refseq | NR_004855 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | liver cancer |
| ICD-0-3 | C22.0 |
| Methods | qPCR, RNAi, Western blot, ChIP, Luciferase reporter assay etc. |
| Sample | HCC tissues, cell lines (HepG2, Huh7, HepG2.2.15 etc.) |
| Expression Pattern | up-regulated |
| Function Description | Levels of HULC were positively correlated with levels of SPHK1 and its product, sphingosine-1-phosphate (S1P), in patients HCC samples. HULC increased SPHK1 in hepatoma cells. Mechanistically, HULC activated the promoter of SPHK1 in hepatoma cells through the transcription factor E2F1. Chromatin immunoprecipitation (ChIP) and electrophoretic mobility shift assay (EMSA) further showed that E2F1 was capable of binding to the E2F1 element in the SPHK1 promoter. HULC increased the expression of E2F1 in hepatoma cells and levels of HULC were positively correlated with those of E2F1 in HCC tissues. Intriguingly, HULC sequestered miR-107, which targeted E2F1 mRNA 3'UTR, by complementary base pairing. Functionally, si-SPHK1 remarkably abolished the HULC-enhanced tumor angiogenesis in vitro and in vivo. |
| Pubmed ID | 26540633 |
| Year | 2015 |
| Title | Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1). |
External Links
| Links for HULC | GenBank HGNC NONCODE |
| Links for liver cancer | OMIM COSMIC |